766 related articles for article (PubMed ID: 17343318)
1. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
[TBL] [Abstract][Full Text] [Related]
2. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
5. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
Russo RA; Katsicas MM
J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
7. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
8. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
[TBL] [Abstract][Full Text] [Related]
9. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
10. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
11. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
14. Response of pediatric uveitis to tumor necrosis factor-α inhibitors.
Lerman MA; Burnham JM; Chang PY; Daniel E; Foster CS; Hennessy S; Jabs DA; Joffe MM; Kaçmaz RO; Levy-Clarke GA; Mills MD; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Kempen JH
J Rheumatol; 2013 Aug; 40(8):1394-403. PubMed ID: 23818712
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
16. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
17. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
[TBL] [Abstract][Full Text] [Related]
18. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
[TBL] [Abstract][Full Text] [Related]
19. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
